Jounce Therapeutics to Participate in a Virtual Fireside Chat at Cowen 2020 IO Next Summit
09 nov. 2020 08h00 HE
|
Jounce Therapeutics, Inc.
CAMBRIDGE, Mass., Nov. 09, 2020 (GLOBE NEWSWIRE) -- Jounce Therapeutics, Inc. (NASDAQ: JNCE), a clinical-stage company focused on the discovery and development of novel cancer immunotherapies and...
Jounce Therapeutics Appoints Robert Iannone, M.D., M.S.C.E., to its Board of Directors
23 janv. 2020 08h00 HE
|
Jounce Therapeutics, Inc.
CAMBRIDGE, Mass., Jan. 23, 2020 (GLOBE NEWSWIRE) -- Jounce Therapeutics, Inc. (NASDAQ: JNCE), a clinical-stage company focused on the discovery and development of novel cancer immunotherapies and...
Jounce Therapeutics Names Jacquelyn Fahey Sandell as Chief Legal Officer and Corporate Secretary
17 sept. 2019 08h00 HE
|
Jounce Therapeutics, Inc.
CAMBRIDGE, Mass., Sept. 17, 2019 (GLOBE NEWSWIRE) -- Jounce Therapeutics, Inc. (NASDAQ: JNCE), a clinical-stage company focused on the discovery and development of novel cancer immunotherapies and...